CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases

11 10 2022 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

06 10 2022 08:00:02 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

26 9 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

10 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

06 9 2022 08:00:04 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

29 8 2022 13:58:30 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

11 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

18 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

17 5 2022 08:00:04 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

12 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

06 4 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

17 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

01 3 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

28 2 2022 08:00:02 提供 Nasdaq GlobeNewswire

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

11 1 2022 08:00:02 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

10 1 2022 08:00:04 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

14 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

09 11 2021 16:30:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

09 11 2021 08:00:04 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

01 11 2021 07:05:00 提供 Nasdaq GlobeNewswire